TY - JOUR
T1 - Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma
T2 - An international multicentre analysis
AU - May, Taymaa
AU - Bernardini, Marcus
AU - Lheureux, Stephanie
AU - Aben, Katja K.H.
AU - Bandera, Elisa V.
AU - Beckmann, Matthias W.
AU - Benitez, Javier
AU - Berchuck, Andrew
AU - Bjørge, Line
AU - Carney, Michael E.
AU - Cramer, Daniel W.
AU - Defazio, Anna
AU - Dörk, Thilo
AU - Eccles, Diana M.
AU - Friedlander, Michael
AU - García, María Jose
AU - Goode, Ellen L.
AU - Hein, Alexander
AU - Jensen, Allan
AU - Johnatty, Sharon
AU - Kennedy, Catherine J.
AU - Kiemeney, Lambertus A.
AU - Kjær, Susanne K.
AU - Kupryjanczyk, Jolanta
AU - Matsuo, Keitaro
AU - McGuire, Valerie
AU - Modugno, Francesmary
AU - Paddock, Lisa E.
AU - Pejovic, Tanja
AU - Phelan, Catherine M.
AU - Riggan, Marjorie J.
AU - Rodriguez-Antona, Cristina
AU - Rothstein, Joseph H.
AU - Sieh, Weiva
AU - Song, Honglin
AU - Terry, Kathryn L.
AU - Altena, Anne M.Van
AU - Vanderstichele, Adriaan
AU - Vergote, Ignace
AU - Thomsen, Liv Cecilie Vestrheim
AU - Webb, Penelope M.
AU - Wentzensen, Nicolas
AU - Wilkens, Lynne R.
AU - Ziogas, Argyrios
AU - Jiang, Haiyan
AU - Tone, Alicia
N1 - Publisher Copyright:
© 2023 Canadian Medical Association. All rights reserved.
PY - 2023/6
Y1 - 2023/6
N2 - Background: Women with low-grade ovarian serous carcinoma (LGSC) benefit from surgical treatment; however, the role of chemotherapy is controversial. We examined an international database through the Ovarian Cancer Association Consortium to identify factors that affect survival in LGSC. Methods: We performed a retrospective cohort analysis of patients with LGSC who had had primary surgery and had overall survival data available. We performed univariate and multivariate analyses of progression-free survival and overall survival, and generated Kaplan-Meier survival curves. Results: Of the 707 patients with LGSC, 680 (96.2%) had available overall survival data. The patients' median age overall was 54 years. Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible residual disease. Of the 361 patients with chemotherapy data, 330 (91.4%) received first-line platinum-based chemotherapy. The median follow-up duration was 5.0 years. The median progression-free survival and overall survival were 43.2 months and 110.4 months, respectively. Multivariate analysis indicated a statistically significant impact of stage and residual disease on progression-free survival and overall survival. Platinum-based chemotherapy was not associated with a survival advantage. Conclusion: This multicentre analysis indicates that complete surgical cytoreduction to no visible residual disease has the most impact on improved survival in LGSC. This finding could immediately inform and change practice.
AB - Background: Women with low-grade ovarian serous carcinoma (LGSC) benefit from surgical treatment; however, the role of chemotherapy is controversial. We examined an international database through the Ovarian Cancer Association Consortium to identify factors that affect survival in LGSC. Methods: We performed a retrospective cohort analysis of patients with LGSC who had had primary surgery and had overall survival data available. We performed univariate and multivariate analyses of progression-free survival and overall survival, and generated Kaplan-Meier survival curves. Results: Of the 707 patients with LGSC, 680 (96.2%) had available overall survival data. The patients' median age overall was 54 years. Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible residual disease. Of the 361 patients with chemotherapy data, 330 (91.4%) received first-line platinum-based chemotherapy. The median follow-up duration was 5.0 years. The median progression-free survival and overall survival were 43.2 months and 110.4 months, respectively. Multivariate analysis indicated a statistically significant impact of stage and residual disease on progression-free survival and overall survival. Platinum-based chemotherapy was not associated with a survival advantage. Conclusion: This multicentre analysis indicates that complete surgical cytoreduction to no visible residual disease has the most impact on improved survival in LGSC. This finding could immediately inform and change practice.
UR - http://www.scopus.com/inward/record.url?scp=85166274935&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85166274935&partnerID=8YFLogxK
U2 - 10.1503/cjs.017020
DO - 10.1503/cjs.017020
M3 - Article
C2 - 37369443
AN - SCOPUS:85166274935
SN - 0820-3946
VL - 66
SP - E310-E320
JO - CMAJ
JF - CMAJ
IS - 3
ER -